Piramal Trims Research To Build Companions Of Neuraceq
This article was originally published in PharmAsia News
Executive Summary
Piramal Lifesciences has cut its research focus, eliminating drugs in the early stage development. Instead, the company will build on products that can be “companion products” to its newly launched flagship brand Neuraceq, used to detect symptoms associated with Alzheimer’s disease.